Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Newegg Commerce Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Newegg Commerce Inc trades at $14.31 (market cap $314.92M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 14.3× Newegg Commerce Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | NEGG | |
|---|---|---|
Market Cap | $4.49B | $314.92M |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $128.09 |
52-Week Low | $20.06 | $14.72 |
Enterprise Value | $3.69B | $313.72M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
NEGG trades at $14.94 with minimal daily movement (+0.2%). The stock shows mixed signals with a bearish technical outlook but positive analyst sentiment. Recent financials reveal modest revenue growth to $1.44B in 2025, though profitability remains challenged with a net loss of $4.88M. The company is investing in AI shopping experiences and promotional events to drive growth.
While analyst consensus is bullish (100% buy rating), fundamental weaknesses including negative cash flow from operations and thin margins present risks. The stock's valuation appears stretched with a P/E of 57.14, suggesting limited near-term upside without significant earnings improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
